Directors
Tetsuo FujiokaChairman
Fujioka joined a food company in 1980 and worked for development of powder and granular material handling machinery, plant design and construction. In 1991, he joined a major engineering company, and served as engineering manager, project manager, project director and department director responsible for pharmaceutical factory projects in Japan as well as overseas for 20 years.
In August 2009, he joined CM Plus Corporation. He takes always a leading role in life science projects with a spirit of “go along with the customer”. He is fully competent to operate a wide variety of services, covering architectural equipment, manufacturing facility, estimate and evaluation, procurement, detailed design, construction management and C & Q. He participated in the EM COP and the Maintenance COP of ISPE Japan. He became company director in September 2015, and promoted to President in August 2016, then appointed to Chairman of CM Plus Japan in July 2020.
Satoshi SuekanePresident
Suekane joined a major engineering company in 1985 and assigned to construction management tasks of domestic and foreign chemical plants. Then, he was transferred to Life Science Project Department in 1989 and appointed to engineering manager and project manager responsible for various sorts of project such as synthetic drugs, eye drops, solid formulations, bio and injections etc. He was finally promoted to a group leader of the Project Department.
The ISPE Facility of the Year 2009 Finalist was awarded to the project successfully managed by him.
He was moved to the Overseas Projects Department in 2009, and became responsible for management of mega-sized projects as the project control manager or engineering manager.
He joined CM Plus Corporation in October 2014 and actively engaged in life science projects. He was appointed to a member of the Board in Sept. 2015, then promoted to Senior Vice President in April 2018. From July 2020, he is President of CM Plus Japan.
Syunichi HirashimaExecutive Vice President
Hirashima joined Fujisawa Pharmaceutical Co., Ltd. (now Astellas Pharna Inc.) in1980. He was engaged in the production of pharmaceutical products and quality assurance for 37 years. Meanwhile, he was appointed to the president in Astellas pharma Tech Co., Ltd. and successfully managed all the domestic group plants. Then, he was appointed to the head of the quality department being globally responsible including Japan, US and Europe of Astellas Pharma Inc. He has got thorough knowledge of site problems as well as management regarding pharmaceutical manufacture.
He joined CM Plus in January 2017 as a member of the Board. He was appointed to Senior Vice President in April 2018, then promoted to Executive Vice President in July 2020.
Toru ItabashiSenior Vice president
Itabashi joined a major engineering company in 1983, and he had been engaged in the domestic and overseas financial management for 34 years. During his service, he was appointed to Business Strategy Department Manager, Business Development Dept. Manager, and Deputy General Manager of the No. 3 Projects Division. Meanwhile, he spent 6 years overseas in Iran, UK, etc. He also served as Vice President of a subsidiary in Japan. In 2013, he was promoted to Associate Director.
He joined CM Plus Corporation in July 2017. He served as Manager of Open Seminar Dept., Group Administration Div., a statutory auditor, and became Senior Vice President in April 2018.
Executive Officers
Susumu MachidaExecutive Officer & Executive Vice President
Machida joined a major engineering company in 1989 and assigned to the task of engineering and project management of pharmaceutical plant. He engaged in the plant design for biotechnological API, sterile drugs, solid dosages, chemical API including qualification/validation activities. He was a founding member of ISPE Japan Affiliate. His contribution includes creation of the Japanese Review of Guideline of Biotechnological API, and subsequently received “Acknowledgement” of appreciation from Mr. Robert P. Best - the President CEO of ISPE International Headquarters.
He joined CM Plus Cooperation in 2010. At CM Plus, he was in charge of animal cell culture PJ, synthetic API PJ, cell processing center PJ , sterile drug product PJ , solid formulation PJ, chemical hazard formulation PJ , SOP creation / CSV review operations.
He was appointed as a member of the Board in September 2013 and further promoted as Managing Director in September 2014. From April 2018, he is Vice President of CM Plus Japan.
Yotaro NakajimaManaging Executive Officer
Nakajima joined a major engineering company in 1992. He has been involved in various facility construction projects including solid dosage form and injection manufacturing facilities, quality control facilities, medical devices, and logistics facilities. He has served as engineering manager and project manager for large projects involving biopharmaceutical API/formulations and high potency solid dosage forms. His experience includes biosafety level 3 containment facilities and single-use biopharmaceutical API plants.
He joined CM Plus in 2019, he was appointed to Executive Officer in July 2022.
Hikohito FujinawaExecutive Officer
Since 1988, has been involved in drug production management, process development and industrialization research at a chemical synthetic drug substance manufacturing plant, and has been involved in Business development, Clinical development of new drugs and generic drugs, Statistical analysis, and application for approval at pharmaceutical companies.
He established Japan's first SMO in 1997, and has experience listing on the First Section of the Tokyo Stock Exchange as a board member (Managing director) and also being a clinical trial coordinator for about 100 clinical trials (including Multi-Regional Clinical Trials) conducted in Japan.
In 2004, he established a CRO and has consulting experience with overseas pharmaceutical companies (including ventures) to enter the Japanese market.
From 2006, he has been involved in reliability assurance (GQP, GVP and Regulatory affairs) divisions for about 15 years as a board member (Director and General Marketing Supervisor：Soukatsu) of domestic and foreign pharmaceutical companies. In the meantime, he has experience in formulation development (Solid formulation ans Sterile formulation : soft-bag formulation), clinical development (GCP), Designated Marketing Authorization Holder (DMAH) Service, M&A, and establishing a Japanese subsidiary of a foreign pharmaceutical company.
In 2020, He joined CM Plus Co., Ltd., where he has been providing consulting services primarily focused on quality assurance and regulatory affairs for Ethical Drugs (including Biological and Cell Therapy Products), Quasi-Drugs, Cosmetics, etc., covering everything from the development stage to post-market product lifecycle management and assumed his current position in July 2024.
Yoshitaka ShimojoExecutive Officer
Shimojo joined Fujisawa Pharmaceutical Co., Ltd. (current Astellas Pharma Inc.) in 1989. He was engaged in the process development, technical transfer etc. for drug substance of antibiotics. Since 2002, he was in charge of planning and administration of CMC (Chemistry, Manufacturing and Controls) (assigned to US subsidiary company in 2006-2008). Since 2013, he was engaged in quality assurance related activities, and fulfilled his role and responsibility as a head of quality audit for global function, then conducted ca. 200 GMP/GDP quality audits and internal audits. He joined CM Plus Co., Ltd. in November 2022 and assumed his current position in July 2024.
Takashi KawashimaExecutive Officer
Kawashima joined a major engineering company in 1988. He has served as a process engineer, project engineer, engineering manager, project manager, and project director for various projects domestic and overseas for nuclear facilities, chemical industries, petrochemical refining, natural gas producing facilities, metal mining facilities, LNG receiving facilities, etc. Served as General Manager of its subsidiary company in Algeria from 2010 to 2011and Division Manager of the Industrial Project Department in headquarter from 2019 to 2020.
He joined CM Plus Corporation in 2023 and has been in the current position since July 2024.
Advisors
Koichi SuzukiChairman and CEO, Internet Initiative Japan Inc.
Born in 1946, Suzuki graduated from Waseda University with a degree in literature, and worked as a business consultant before establishing IIJ, Japan's first commercial internet provider. Suzuki has been playing a leading role in Japanese Internet and communications services and information technology.
Norikazu EikiFormer Chairman of Bayer Yakuhin, Ltd.
Eiki joined Bayer Yakuhin, Ltd. in 1994 after Nihon Ciba-Geigy K.K. He was appointed to a member the Board (Shiga Factory Director) in 1997, Managing Director in 2002, Executive Chairman in 2007 and Chairman of the Board in 2010. After retirement from the company in April 2014, he joined CM Plus Corporation as Adviser.
Founder
Tsunehiro TogashiFounder & Group CEO
Togashi joined a major engineering company in 1973. After 10 year service in the civil and building design department being engaged in design and construction supervision for both domestic and oversea energy plants, he was moved to Domestic Industrial Facility Project Division, and had worked there for 21 years. During this time, he served as project manager for various industrial facility to gain in-depth knowledge of pharmaceutical R&D and manufacturing facilities, electronic and electric device factories, and data centers. He also managed many projects for foreign clients successfully including a research facility project in UK. In 2000, Togashi set up a new organization namely “Facility Management Department” so as to deliver projects with a strong focus on lifecycle costs of facility construction and operations. After retiring from Associate Director in June 2007, he founded CM Plus Corporation in August 2007.
Togashi worked as President, then appointed to Chairman & CEO of CM Plus Corporation in September 2015. In April 2018, he became Founder and Group CEO of CM Plus Group, and cum-Managing Director of CM Plus Singapore. Appointed as a director and adviser of CM Plus Japan from July 2019.
